These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28539706)

  • 21. Involvement of M1 Macrophage Polarization in Endosomal Toll-Like Receptors Activated Psoriatic Inflammation.
    Lu CH; Lai CY; Yeh DW; Liu YL; Su YW; Hsu LC; Chang CH; Catherine Jin SL; Chuang TH
    Mediators Inflamm; 2018; 2018():3523642. PubMed ID: 30647534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection.
    Tabeta K; Georgel P; Janssen E; Du X; Hoebe K; Crozat K; Mudd S; Shamel L; Sovath S; Goode J; Alexopoulou L; Flavell RA; Beutler B
    Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3516-21. PubMed ID: 14993594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TLR activation pathways in HIV-1-exposed seronegative individuals.
    Biasin M; Piacentini L; Lo Caputo S; Naddeo V; Pierotti P; Borelli M; Trabattoni D; Mazzotta F; Shearer GM; Clerici M
    J Immunol; 2010 Mar; 184(5):2710-7. PubMed ID: 20124101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toll-Like Receptor Ligand-Induced Liver Injury in D-Galactosamine-Sensitized Mice: Differences between TLR7/8 and TLR9 Ligands, Cytokine Patterns, and Cross-Tolerance Induction by TLR2 Ligand Pretreatment.
    Seki R
    J Immunol Res; 2017; 2017():9653793. PubMed ID: 29181417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine.
    Wolska A; Cebula-Obrzut B; Smolewski P; Robak T
    Leuk Lymphoma; 2013 Jun; 54(6):1268-78. PubMed ID: 23078646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma.
    Huen AO; Rook AH
    Curr Opin Oncol; 2014 Mar; 26(2):237-44. PubMed ID: 24441505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A human microsatellite DNA-mimicking oligodeoxynucleotide with CCT repeats negatively regulates TLR7/9-mediated innate immune responses via selected TLR pathways.
    Sun R; Sun L; Bao M; Zhang Y; Wang L; Wu X; Hu D; Liu Y; Yu Y; Wang L
    Clin Immunol; 2010 Mar; 134(3):262-76. PubMed ID: 20034855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation.
    Lai CY; Su YW; Lin KI; Hsu LC; Chuang TH
    J Immunol Res; 2017; 2017():7807313. PubMed ID: 28894754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signaling crosstalk during sequential TLR4 and TLR9 activation amplifies the inflammatory response of mouse macrophages.
    De Nardo D; De Nardo CM; Nguyen T; Hamilton JA; Scholz GM
    J Immunol; 2009 Dec; 183(12):8110-8. PubMed ID: 19923461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver transplantation.
    Howell J; Sawhney R; Testro A; Skinner N; Gow P; Angus P; Ratnam D; Visvanathan K
    Liver Transpl; 2013 Oct; 19(10):1099-107. PubMed ID: 23894100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toll-like receptor (TLR) 7 decreases and TLR9 increases the airway responses in mice with established allergic inflammation.
    Adner M; Starkhammar M; Georén SK; Dahlén SE; Cardell LO
    Eur J Pharmacol; 2013 Oct; 718(1-3):544-51. PubMed ID: 24041926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor Development.
    Mohamed FEZ; Jalan R; Minogue S; Andreola F; Habtesion A; Hall A; Winstanley A; Damink SO; Malagó M; Davies N; Luong TV; Dhillon A; Mookerjee R; Dhar D; Al-Jehani RM
    Dig Dis Sci; 2022 May; 67(5):1806-1821. PubMed ID: 33939146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemokine, cytokine and type I interferon production induced by Toll-like receptor activation in common variable immune deficiency.
    Lollo C; de Moraes Vasconcelos D; Oliveira LMDS; Domingues R; Carvalho GC; Duarte AJDS; Sato MN
    Clin Immunol; 2016 Aug; 169():121-127. PubMed ID: 27392462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity.
    Krieg AM; Vollmer J
    Immunol Rev; 2007 Dec; 220():251-69. PubMed ID: 17979852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of TLR-induced inflammatory responses in COPD and control lung tissue explants.
    Pomerenke A; Lea SR; Herrick S; Lindsay MA; Singh D
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2409-2417. PubMed ID: 27729782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toll-like receptors and CD40 modulate each other's expression affecting Leishmania major infection.
    Chandel HS; Pandey SP; Shukla D; Lalsare K; Selvaraj SK; Jha MK; Saha B
    Clin Exp Immunol; 2014 May; 176(2):283-90. PubMed ID: 24387292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines.
    Kuznik A; Bencina M; Svajger U; Jeras M; Rozman B; Jerala R
    J Immunol; 2011 Apr; 186(8):4794-804. PubMed ID: 21398612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma.
    Mohamed FE; Al-Jehani RM; Minogue SS; Andreola F; Winstanley A; Olde Damink SW; Habtesion A; Malagó M; Davies N; Luong TV; Dhillon AP; Mookerjee RP; Dhar DK; Jalan R
    Liver Int; 2015 Mar; 35(3):1063-76. PubMed ID: 24990399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
    Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
    J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9.
    Park B; Brinkmann MM; Spooner E; Lee CC; Kim YM; Ploegh HL
    Nat Immunol; 2008 Dec; 9(12):1407-14. PubMed ID: 18931679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.